导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -10.74% | 3797/4773 |
| 近一周 | -2.29% | 3689/5465 |
| 近一月 | -1.34% | 1117/5421 |
| 近一季 | -0.47% | 1069/5231 |
| 近半年 | -8.99% | 3579/4920 |
| 近一年 | -8.69% | 3332/4394 |
| 近两年 | 27.88% | 2379/2954 |
| 近三年 | 11.55% | 1717/2253 |
| 成立以来 | 3.27% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.72% 4181/4961 |
-5.55% 3591/5312 |
- - |
- - |
| 2025 | 8.56% 2900/4813 |
-7.01% 3417/3635 |
3.55% 994/4076 |
15.15% 2840/4524 |
-2.09% 3088/4813 |
| 2024 | 28.03% 171/3463 |
1.40% 881/2808 |
-2.77% 1248/3014 |
22.19% 500/3129 |
6.28% 526/3463 |
| 2023 | -5.90% 794/2656 |
3.82% 1117/2280 |
-1.33% 475/2385 |
0.84% 337/2515 |
-8.90% 2316/2655 |
| 2022 | -13.05% 312/2207 |
-8.29% 276/1919 |
1.63% 1445/2016 |
-10.66% 437/2113 |
4.42% 549/2208 |
| 2021 | -3.19% 892/1822 |
-2.67% 687/1255 |
-1.60% 1174/1330 |
-0.22% 481/1466 |
1.32% 966/1822 |
| 2020 | -0.40% 942/1250 |
-15.76% 990/1028 |
6.44% 865/1067 |
6.14% 870/1164 |
4.65% 833/1184 |
| 2019 | 21.55% 648/1092 |
23.57% 546/754 |
0.30% 177/804 |
84.81% 1/850 |
2.41% 864/918 |
| 2018 | -20.80% 200/834 |
- - |
- - |
- - |
-9.67% 158/691 |
| 2017 | 1.77% 448/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 汇添富中证上海国企ETF VS. 长安沪深300非周期A(740101) |